PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-80

  1. 2,121 Posts.
    lightbulb Created with Sketch. 568
    PAR003 was meant to start at beginning of H2 this year.

    Now PAR are saying they will consult with FDA in H2 this year on endpoints for 003 for DMOAD label.

    Significant program delays. Pity there wasn’t significant difference in WOMAC scores at six months.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.